奥利司他肠痉挛、肠道产生气体以及油性斑点
FDA只认可奥利司他(赛尼可)可以长期使用。
Only orlistat (Xenical) has been approved by the FDA for long-term use.
后者的代表是含奥利司他或大黄的减肥药。
The latter was represented by his or rhubarb with orlistat weight loss drug.
FDA会尽快发布关于奥利司他的再评价结果。
The FDA will release its findings on orlistat as soon as the review is completed.
对奥利司他而言，脂肪痢是主要的胃肠道副反应。
For orlistat, steatorrhea produces the principal gastrointestinal side effects.
奥利司他可以在胃及肠道中阻止脂肪的消化与吸收。
Orlistat blocks the digestion and absorption of fat in your stomach and intestines.
奥利司他胶囊，不会让你感觉不饿，但是能阻止身体吸收脂肪。
Orlistat doesn't stop you feeling hungry, but it stops your body absorbing some of the fat from the food you eat.
非处方药奥利司他的副作用为排便习惯改变，如排稀便。
The side effects of over the counter Orlistat include disruption to bowel habits, such as looser stools.
在3个月的试验结束时，奥利司他组的血脂水平有了显著改善。
In orlistat group, significant improvement was observed in lipid profile at the end of 3 months.
在每天三次随同吃饭时的服用奥利司他，可以阻隔肠子吸收脂肪。
Orlistat blocks the intestines from absorbing fat when taken up to three times a day with meals.
奥利司他同样适用于在没有处方的形式下的力量削弱(alli)。
Orlistat is also available in a reduced-strength form without a prescription (Alli).
奥利司他和二甲双胍组的排卵率分别是33.3%和23.35%，但无统计学差异。
Ovulation rate was 33.3%, 23.35% with orlistat and metformin group respectively, but were not statistically significant.
同样的，由于发现服用奥利司他会引起严重的肝损伤，FDA近来正在复核使用奥利司他的安全性。
Similarly, the FDA is currently reviewing the safety of orlistat because of reports of serious liver injury in people taking it.
服用奥利司他胶囊后，大部分人会产生如下副反应：排泄物里有油脂，经常腹泻、肚痛，恶心呕吐。
Most people taking orlistat get some of these side effects: an oily leakage from your bowels, diarrhoea which comes on very quickly, frequent wind and nausea and vomiting.
在这些使用奥利司他1年的青少年人群中尽管出现了胃肠道不良反应，但未见其它不安全事件。
The use of orlistat for 1 year in this adolescent population did not raise major safety issues although gastrointestinal adverse events were more common in the orlistat group.
结果表明，非细胞毒性浓度的奥利司他减少了柯萨奇病毒B3 (CVB3)在不同的细胞类型的复制。
The results indicate that administrations of non-cytotoxic concentrations of orlistat reduced the replication of coxsackievirus B3 (CVB3) in different cell types significantly.
英国医学与健康用品协调机构称，自1998年药物奥利司他批准上市以来，已接到1295份疑似与其副作用有关的报告。
Britain's Medicines and Healthcare Products Regulatory Agency said it had received a total of 1, 295 suspected adverse drug reaction reports associated with orlistat since it was licensed in 1998.
结论：在体重的维持期间，奥利司他的使用能够将体重的波动降到最低并能有效改善和肥胖相关的其他风险因子。
Conclusion: The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.
目的探讨非酒精性脂肪性肝病(NAFLD)的发病机制及奥利司他结合低热量饮食治疗对NAFLD的有效性和安全性。
Objective To study the pathogenesis of non alcoholic fatty liver disease (NAFLD) and the efficacy and safety of Orlistat plus low caroli diet in the treatment of NAFLD.
当奥利司他(Xenical)——第一代减肥药在20时间90年代晚期风靡市场后，我曾很乐观的相信它将成为战胜肥胖的一个有力武器。
When orlistat (Xenical), the first of a new generation of slimming pills, hit the market in the late 1990s I was optimistic that it would prove a key weapon in the fight against obesity.
在考虑其可能存在某些毒副作用，美国食品药物管理局年初开始对在柜台里名为Alli，主要成份是奥利司他的减肥药进行调查，看它是否与那些肝损害案例有关。
The FDA began investigating orlistat, sold over the counter as Alli, and its potential links to liver damage earlier this year after concerns were raised about potentially harmful side effects.
FDA的公告称，自1999到2008年间，他们共接到32起服用奥利司他的病人出现肝脏损伤的报告，其中的27例进行了住院治疗，6例出现肝功能衰竭迹象。
Between 1999 and 2008, the FDA received 32 reports of serious liver injury in patients taking orlistat. Of those cases, 27 reported hospitalization and six resulted in liver failure.
FDA的公告称，自1999到2008年间，他们共接到32起服用奥利司他的病人出现肝脏损伤的报告，其中的27例进行了住院治疗，6例出现肝功能衰竭迹象。
Between 1999 and 2008, the FDA received 32 reports of serious liver injury in patients taking orlistat. Of those cases, 27 reported hospitalization and six resulted in liver failure.
应用推荐